The antiviral drug remdesivir, which allegedly helped US President Donald Trump recover from the coronavirus, is not actually intended for COVID-19 patients, which is why the World Health Organization (WHO) is not recommending its use in hospitals.
This statement was made on Friday, November 20, representatives of the organization in Geneva, citing the conclusions of an international group of experts involved in the development of guidelines for the use of drugs. The Wall Street Journal.
As noted in the statement, “remdesivir is not intended for patients with COVID-19 admitted to hospital for treatment, regardless of the severity of their illness, as there is currently no evidence that it improves survival or reduces the need for ventilation.”
The WHO recalled that “remdesivir has attracted worldwide attention as a potentially effective treatment for severe COVID-19.” It is “increasingly used to treat patients in hospitals, but its role in clinical practice remains uncertain.” The experts explained that their “today’s recommendation is based on a new examination of the evidence”. In particular, the results of four international trials involving more than 7 thousand patients were taken into account.
After carefully examining this data, a group of experts from around the world and four former patients “concluded that remdesivir had no significant effect on mortality or other important patient outcomes, such as the need for mechanical ventilation [легких] or the time of clinical improvement. “
Previously, WHO stated that only corticosteroids such as dexamethasone and hydrocortisone have proven effective in treating severe forms of coronavirus infection. In turn, the drugs remdesivir, hydroxychloroquine, lopinavir / ritonavir and interferon, which have been actively studied, according to the organization, have almost no effect in the treatment of COVID-19 in a hospital setting in terms of reducing mortality. In October, WHO announced that it would publish guidelines for the use of remdesivir within a month.
The American pharmaceutical company Gilead Sciences, which developed remdesivir, previously claimed that its use would shorten the COVID-19 convalescence period to four days. A number of countries, including the United States, Japan and the United Kingdom, have approved the use of the drug to treat those infected with the coronavirus. It was originally created as part of testing for the treatment of hepatitis C and respiratory syncytial virus.
At the same time, after the WHO statement, the Ministry of Health, Labor and Welfare of Japan announced that it does not intend to revise the approval for the use of remdesivir for the treatment of patients with coronavirus at the moment.
“In Japan, patients are being treated with remdesivir, which was approved in May in connection with the identification of a certain efficacy of this drug in a number of clinical trials, as well as based on permission for its use in the United States. As far as I know, at the moment the Ministry of Health does not consider it necessary to reconsider the decision on the approval of remdesivir “– said at a press conference the secretary general of the Japanese cabinet of ministers Katsunobu Kato.
Earlier, “FACTS” wrote that during a working visit to the Dnipropetrovsk region Minister of Health Maxim Stepanov saidthat Remdesivir began to enter hospitals in the regions of Ukraine. Perhaps, after the statement by WHO, the decision will be reconsidered.